Skip to main content

NASDAQ:COCP - Cocrystal Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.75
  • Forecasted Upside: 259.85 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.32
▼ -0.08 (-5.71%)
1 month | 3 months | 12 months
Get New Cocrystal Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COCP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COCP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$4.75
▲ +259.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cocrystal Pharma in the last 3 months. The average price target is $4.75, with a high forecast of $5.00 and a low forecast of $4.50. The average price target represents a 259.85% upside from the last price of $1.32.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Cocrystal Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2020Noble FinancialReiterated RatingBuy$5.00Low
i
11/12/2020HC WainwrightLower Price TargetBuy$5.00 ➝ $4.50High
i
7/8/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by R. Selvaraju at HC Wainwright
7/8/2020HC WainwrightInitiated CoverageBuy$5.00High
i
6/16/2020Noble FinancialInitiated CoverageOutperform$5.00High
i
7/17/2018EuroPacific CanadaInitiated CoverageBuy$14.00N/A
i
(Data available from 5/9/2016 forward)
Cocrystal Pharma logo
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $1.32
$1.30
$1.40

50 Day Range

MA: $1.36
$1.13
$2.14

52 Week Range

Now: $1.32
$0.76
$3.46

Volume

20,644,989 shs

Average Volume

11,537,608 shs

Market Capitalization

$94.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Cocrystal Pharma?

The following Wall Street research analysts have issued stock ratings on Cocrystal Pharma in the last twelve months: HC Wainwright, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for COCP.

What is the current price target for Cocrystal Pharma?

2 Wall Street analysts have set twelve-month price targets for Cocrystal Pharma in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 259.8%. Noble Financial has the highest price target set, predicting COCP will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.50 for Cocrystal Pharma in the next year.
View the latest price targets for COCP.

What is the current consensus analyst rating for Cocrystal Pharma?

Cocrystal Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COCP will outperform the market and that investors should add to their positions of Cocrystal Pharma.
View the latest ratings for COCP.

What other companies compete with Cocrystal Pharma?

How do I contact Cocrystal Pharma's investor relations team?

Cocrystal Pharma's physical mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The company's listed phone number is 786 459 1831 and its investor relations email address is [email protected] The official website for Cocrystal Pharma is www.cocrystalpharma.com.